HS
RCKT icon

HighVista Strategies’s Rocket Pharmaceuticals RCKT Stock Holding History

HighVista Strategies’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-48,191
Closed -$764K – 114
2022
Q1 		$764K Buy
48,191
+1,278
+3% +$22.1K 0.49% 60
2021
Q4 		$1.02M Buy
46,913
+6,242
+15% +$170K 0.82% 45
2021
Q3 		$1.22M Buy
40,671
+22,247
+121% +$810K 0.8% 35
2021
Q2 		$816K Buy
18,424
+4,088
+29% +$178K 0.58% 39
2021
Q1 		$636K Sell
14,336
-10,231
-42% -$562K 0.47% 54
2020
Q4 		$1.35M Buy
24,567
+7,225
+42% +$263K 0.86% 21
2020
Q3 		$396K Sell
17,342
-7,682
-31% -$189K 0.29% 66
2020
Q2 		$524K Buy
+25,024
New +$451K 0.43% 20

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

HighVista Strategies's RCKT Position: Q2 2022 in Review

HighVista Strategies sold out of Rocket Pharmaceuticals (RCKT) in Q2 2022, closing a stake of 48,191 shares — an estimated $764K sold.

HighVista Strategies first reported a position in RCKT in Q2 2020 and held it in 8 quarters. The position peaked at $1.35M in Q4 2020. 147 funds tracked by Wall St. Rank hold RCKT as of Q2 2022.

  • HighVista Strategies reported no remaining Rocket Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • HighVista Strategies sold 48,191 Rocket Pharmaceuticals shares in Q2 2022, an estimated $764K.
  • HighVista Strategies first reported a position in Rocket Pharmaceuticals in Q2 2020 and held it in 8 quarters.
  • HighVista Strategies's Rocket Pharmaceuticals position peaked at $1.35M in Q4 2020.
  • 147 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2022.

Based on HighVista Strategies's 13F filing for Q2 2022, filed 15 Aug 2022.